B+
Bull case
30%
Probability
Target price
$52.00
Analysis reference price unavailable
Analysis 2026-05-04 · RankAlpha Sentiment Codex
TVTX
Travere TherapeuticsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+1Most likely
B
Base case
45%
Probability
Target price
$43.00
Analysis reference price unavailable
Analysis 2026-05-04 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$34.00
Analysis reference price unavailable
Analysis 2026-05-04 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-05-04
Recent news sentiment (30D)
+0.7
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+25.9
Score
AI commentary
Headline tone is positive because recent coverage centered on FILSPARI's April 13, 2026 FDA approval in FSGS and the stock's sharp post-approval move. But this is still a monitoring-style T+1 earnings memo: as of May 4, 2026, the checked primary sources confirmed only the scheduled timing of the Q1 release, not the actual earnings results, guidance, analyst revisions, or a verified post-print market reaction. That missing earnings confirmation keeps conviction below what the strong pre-existing approval narrative alone would imply.
RankAlpha Sentiment Codex - 2026-05-04
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-04eventQ1 2026 earnings release timing is confirmed, but results were not yet verified in checked primary sourcesHigh impact
Travere said on April 27, 2026 that it plans to report first-quarter 2026 financial results on May 4, 2026 after the U.S. market close and host a 4:30 p.m. ET call; as of May 4, 2026, no Q1 earnings release or 8-K was verified in the primary sources checked, so earnings surprise, guidance changes, and analyst revisions remain unconfirmed [#IR-2026-04-27].
2026-06-30eventExpected first-half 2026 milestone payment can modestly support liquidityMedium impact
Travere's February 19, 2026 investor-relations earnings release said year-end cash, cash equivalents, and marketable securities were $322.8 million and that the company expects a $25 million sales-based milestone payment from Mirum Pharmaceuticals in the first half of 2026, which could modestly reinforce balance-sheet flexibility while the company funds launch and pipeline work [#IR-2026-02-19].
2026-06-30catalystFILSPARI FSGS launch conversion after April approvalHigh impact
Travere's April 13, 2026 8-K says FDA approved FILSPARI to reduce proteinuria in adult and pediatric FSGS patients without nephrotic syndrome, making it the first approved medicine for FSGS; the filing also says Travere estimates a U.S. addressable population of more than 30,000 and highlighted favorable DUPLEX subgroup data, so the next debate is how much of that approval converts into durable launch demand [#8-K-2026-04-14].
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-04 • Updated nightlySource: Internal modelMethodology